Product Description
CT-95 is a fully humanized bispecific TCE that employs an IgG-scFv architecture with an effector-silenced IgG1 backbone and has a relatively low affinity but high avidity for membrane-bound MSLN, minimizing the impact of the shed sink. CT-95 is being developed as a therapy for advanced cancers associated with MSLN expression. (Sourced from: https://www.benzinga.com/pressreleases/24/07/g39706248/context-therapeutics-acquires-phase-1-ready-t-cell-engager-ct-95)
Mechanisms of Action: MSLN Inhibitor,CD3 Inhibitor
Novel Mechanism: Yes
Modality: Bispecific Antibody
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Context
Company Location: PHILADELPHIA PA 19104
Company CEO: Martin Lehr
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for CT-95](https://pryzm-maps.s3.us-west-2.amazonaws.com/666666current_maps.png)
Countries in Clinic:
Active Clinical Trial Count:
Highest Development Phases
Phase 1: Oncology Solid Tumor Unspecified
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|